MEDI4736 monotherapy

BIOLOGICAL2 trials

Sponsors

AstraZeneca

Conditions

Metastatic Pancreatic Ductal AdenocarcinomaPancreatic Ductal AdenocarcinomaTriple-negative Breast CancerUrothelial Bladder Cancer

Phase 2

Study of Tremelimumab in Patients With Advanced Solid Tumors

CompletedNCT02527434

AstraZenecaPancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer, Urothelial Bladder Cancer

Start: 2015-11-02End: 2023-03-28Updated: 2023-11-15

Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma

CompletedNCT02558894

AstraZenecaMetastatic Pancreatic Ductal Adenocarcinoma

Start: 2015-11-16End: 2017-06-15Updated: 2018-08-02

Related Papers

Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy

Clinical Cancer Research2019-12-0443 citations

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

JAMA Oncology2019-07-18721 citations

A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.

Journal of Clinical Oncology2018-02-0134 citations

Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma.

Journal of Clinical Oncology2018-02-0123 citations

A phase 2, open-label, multicenter study of durvalumab (MEDI4736) ± tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS.

Journal of Clinical Oncology2016-05-203 citations